Dimensional Fund Advisors LP Acquires 26,540 Shares of Glaukos Co. (NYSE:GKOS)

Dimensional Fund Advisors LP lifted its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 9.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 312,314 shares of the medical instruments supplier's stock after buying an additional 26,540 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.57% of Glaukos worth $46,828,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Forum Financial Management LP bought a new stake in Glaukos in the fourth quarter worth $211,000. CANADA LIFE ASSURANCE Co raised its stake in Glaukos by 0.9% during the 4th quarter. CANADA LIFE ASSURANCE Co now owns 64,929 shares of the medical instruments supplier's stock valued at $9,751,000 after buying an additional 601 shares during the last quarter. Farringdon Capital Ltd. bought a new position in shares of Glaukos during the 4th quarter valued at $244,000. Evergreen Capital Management LLC boosted its stake in shares of Glaukos by 5.4% in the 4th quarter. Evergreen Capital Management LLC now owns 3,472 shares of the medical instruments supplier's stock worth $521,000 after buying an additional 177 shares during the last quarter. Finally, Barclays PLC grew its holdings in shares of Glaukos by 2.3% in the fourth quarter. Barclays PLC now owns 91,785 shares of the medical instruments supplier's stock worth $13,762,000 after acquiring an additional 2,086 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on GKOS. Piper Sandler dropped their target price on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 15th. Morgan Stanley decreased their price target on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research report on Tuesday. Mizuho reduced their price objective on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research note on Wednesday, April 16th. Stifel Nicolaus lowered their target price on Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. Finally, Wells Fargo & Company downgraded Glaukos from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $160.00 to $86.00 in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Glaukos Price Performance

Shares of GKOS traded up $0.49 during mid-day trading on Thursday, hitting $88.73. 113,793 shares of the stock were exchanged, compared to its average volume of 675,920. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The company has a market cap of $5.07 billion, a PE ratio of -30.92 and a beta of 0.83. Glaukos Co. has a 52-week low of $77.10 and a 52-week high of $163.71. The firm has a 50-day moving average of $95.68 and a two-hundred day moving average of $127.93.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same quarter in the prior year, the firm earned ($0.70) earnings per share. Glaukos's revenue was up 24.6% on a year-over-year basis. On average, equities analysts predict that Glaukos Co. will post -1.08 earnings per share for the current year.

Insider Activity at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.